1α,25-dihydroxyvitamin D3-26,23-lactam, a novel vitamin D3 analog, acts as a vitamin D3 antagonist in human prostate cancer cells
-
- Takita Morichika
- Department of Biotechnology and Life Science, Tokyo University of Agriculture and Technology
-
- Hirata Michiko
- Department of Biotechnology and Life Science, Tokyo University of Agriculture and Technology
-
- Tsukamoto Kazuki
- Department of Biotechnology and Life Science, Tokyo University of Agriculture and Technology
-
- Nagasawa Kazuo
- Department of Biotechnology and Life Science, Tokyo University of Agriculture and Technology
-
- Miyaura Chisato
- Department of Biotechnology and Life Science, Tokyo University of Agriculture and Technology
-
- Inada Masaki
- Department of Biotechnology and Life Science, Tokyo University of Agriculture and Technology
書誌事項
- タイトル別名
-
- 1.ALPHA.,25-Dihydroxyvitamin D3-26,23-lactam, a Novel Vitamin D3 Analog, Acts as a Vitamin D3 Antagonist in Human Prostate Cancer Cells
- 1 a 25 dihydroxyvitamin D3 26 23 lactam a novel vitamin D3 analog acts as a vitamin D3 antagonist in human prostate cancer cells
この論文をさがす
抄録
1α,25-Dihydroxyvitamin D3 [1α,25(OH)2D3], the active form of vitamin D3, is known to exhibit an anti-tumor properties and markedly suppresses the growth of various human cancer cells. We synthesized novel vitamin D analogs, 1α,25-dihydroxyvitamin D3-26,23-lactam (DLAMs), having a lactam moiety in the side chain, and examined the effects on cell growth of human prostate cancer cells LNCaP. 1α,25(OH)2D3 significantly suppressed both the number of cells and cell viability. The mRNA expression of p21, well-known as a tumor suppressive gene, was clearly induced by treatment with 1α,25(OH)2D3 in LNCaP cells. The effects of 1α,25(OH)2D3 on the growth suppression of LNCaP cells was attenuated by the simultaneous addition of (23S,25S)-DLAM-1P. In a computer docking simulation, (23S,25S)-DLAM-1P bound to vitamin D receptor (VDR), and its lactam moiety may interfere VDR helix-12 folding. Its stereoisomer (23R,25R)-DLAM-1P did not influence cell growth regulated by 1α,25(OH)2D3. The expression of p21 mRNA induced by 1α,25(OH)2D3 was suppressed by (23S,25S)-DLAM-1P but not by (23R,25R)-DLAM-1P in LNCaP cells. In the absence of 1α,25(OH)2D3, neither (23S,25S)-DLAM-1P nor (23R,25R)-DLAM-1P regulated the cell growth of LNCaP cells. Thus, (23S,25S)-DLAM-1P interferes with the VDR signal and acts as a vitamin D3 antagonist in cancer cells.
収録刊行物
-
- JOURNAL OF HEALTH SCIENCE
-
JOURNAL OF HEALTH SCIENCE 54 (4), 497-502, 2008
公益社団法人 日本薬学会
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1390001204498912640
-
- NII論文ID
- 110006835698
-
- NII書誌ID
- AA11316464
-
- ISSN
- 13475207
- 13449702
-
- NDL書誌ID
- 9592683
-
- 本文言語コード
- en
-
- データソース種別
-
- JaLC
- NDL
- Crossref
- CiNii Articles
-
- 抄録ライセンスフラグ
- 使用不可